Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 6/20 | 0.42 |
| ▸ | NEK1 | Q96PY6 | 3/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600533 | 0.91 | ABL1 (0.54) | ABL1MAP4K1GPBAR1POLQ | |
| SCHEMBL2600527 | 0.90 | ABL1 (0.57) | ABL1MAP4K1CYP3A4IGF1RTNIK | |
| SCHEMBL2600562 | 0.88 | ABL1 (0.51) | ABL1MAP4K1CYP3A4IGF1RNEK1 | |
| SCHEMBL2600544 | 0.88 | ABL1 (0.51) | ABL1MAP4K1CYP3A4IGF1RNEK1 | |
| SCHEMBL2600547 | 0.87 | ABL1 (0.50) | ABL1MAP4K1CYP3A4IGF1RNEK1 | |
| SCHEMBL2600560 | 0.85 | MAP4K1 (0.50) | ABL1MAP4K1CYP3A4IGF1RNEK1 | |
| SCHEMBL2600548 | 0.84 | ABL1 (0.48) | ABL1MAP4K1CYP3A4IGF1RNEK1 | |
| SCHEMBL2600530 | 0.83 | ABL1 (0.67) | ABL1MAP4K1IGF1RGPBAR1 | |
| SCHEMBL2600556 | 0.79 | ABL1 (0.58) | ABL1MAP4K1CYP3A4NEK1POLQ | |
| SCHEMBL2600564 | 0.79 | ABL1 (0.58) | ABL1MAP4K1CYP3A4NEK1POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | ABL1 862/4885MAP4K1 16/4885CYP3A4 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.